Spironolactone
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Spironolactone: From Edema/Hypertension to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Spironolactone is a long-established aldosterone receptor antagonist used clinically for fluid retention, hypertension, and related conditions (specific original indication text unavailable — drug is not marketed in New Zealand). The TxGNN model predicts it may be effective for Hypotrichosis Simplex of the Scalp, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal with no corroborating real-world evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (drug not marketed in New Zealand; no license text on file) |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this candidate. Based on known pharmacology, spironolactone is an aldosterone receptor antagonist with secondary anti-androgenic activity; this anti-androgenic effect is the basis for its established off-label use in female-pattern androgenetic alopecia (androgen-driven hair loss).
However, the predicted indication here — hypotrichosis simplex of the scalp — is a distinct, genetically driven condition (typically linked to APCDD1 mutations disrupting Wnt signaling in hair follicle development) with no known hormonal or androgen-pathway component. The second-ranked prediction, congenital hypotrichosis with milia, is similarly a congenital keratinization/follicle-development disorder (associated with HR-gene or related pathways), again without an established androgen or mineralocorticoid link.
The evidence pack's own mechanistic rationale flags this directly: the high TxGNN score most likely reflects proximity between "hypotrichosis" and "alopecia" phenotype nodes within the knowledge graph, rather than a genuine shared biological mechanism. Without any supporting trials or literature, this prediction should be treated as a hypothesis-generating artifact rather than a validated mechanistic link.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Spironolactone is not currently marketed in New Zealand, and no product authorizations are on record (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN graph-similarity score (L5) with zero corroborating clinical trials or literature, and the proposed indications (genetic/congenital hypotrichosis) lack a plausible mechanistic connection to spironolactone's known antimineralocorticoid/anti-androgenic activity. Compounding this, the drug is not marketed in New Zealand and core safety data (warnings, contraindications, DDI) are unavailable, blocking any S1 safety review.
To proceed, the following is needed:
- TFDA/official package insert data (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action data from DrugBank or primary literature
- Preclinical or mechanistic evidence directly linking spironolactone's pathway to APCDD1/Wnt or HR-gene/keratinization biology, to rule out graph-proximity artifact
- Drug-drug interaction data
- Reassessment if any clinical trials or case literature for these specific indications emerge
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.